AstraZeneca PLC (AZN)vsGenmab AS (GMAB)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
GMAB
Genmab AS
$25.15
+1.70%
HEALTHCARE · Cap: $15.40B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1449% more annual revenue ($60.44B vs $3.90B). GMAB leads profitability with a 21.0% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.39. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
GMAB
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
+46.6%
Fair Value
$56.30
Current Price
$25.15
$31.15 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Keeps 21 of every $100 in revenue as profit
Reasonable price relative to book value
Strong operational efficiency at 25.1%
Revenue surging 25.3% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Distress zone — elevated risk
Weak financial health signals
Earnings declined 72.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : GMAB
The strongest argument for GMAB centers on Profit Margin, Price/Book, Operating Margin. Profitability is solid with margins at 21.0% and operating margin at 25.1%. Revenue growth of 25.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Altman Z-Score, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while GMAB is a growth play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.68 — expect wider price swings.
GMAB is growing revenue faster at 25.3% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 62/100), backed by strong 17.2% margins and 12.5% revenue growth. GMAB offers better value entry with a 46.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?